An Emulated Target Trial Case Study of Real‐World Overall Survival With Second‐Line Maintenance Niraparib Versus Active Surveillance in Patients With Recurrent Ovarian Cancer
This real-world study provides supportive evidence of an OS benefit for patients with BRCAwt recurrent OC who received 2LM niraparib monotherapy compared with those whose care was managed with AS. The analytic strategies implemented were useful in minimizing immortal time bias and measured confounding.
Authors
- Jessica Perhanidis (ORCID: https://orcid.org/0000-0001-6943-8500)
- Linda Kalilani
- Nicole M. Zimmerman
- Amanda Golembesky
Institutions
- Providence College (US)
Publication Details
- Journal
- Pharmacoepidemiology and Drug Safety
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1002/pds.70001
- Citations
- 1
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.28
Funders
- GlaxoSmithKline